---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-389400"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2026-09-11T21:15:06+00:00"
generated_at: "2026-09-11T21:16:14.001928+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# ACADIA derivative settlement preliminarily approved; governance reforms, $1.5M fees

## Summary
- Court granted preliminary approval on Aug 24, 2026; final hearing set Jan 13, 2027 in San Diego.
- Settlement requires maintaining corporate governance reforms for at least 4 years; no stockholder cash payments.
- Stockholders' counsel to receive $1.5M in fees; service awards up to $5,000 each, court-approved.
- Derivative claims trace to alleged misstatements on Nuplazid sNDA; FDA CRL in Apr 2021 cut shares >45% and 17%.
- Objections due Dec 23, 2026; claims are derivative, not class action, and release all related demands.

## SEC filing metadata
- accession: 0001193125-26-389400
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2026-09-11T21:15:06+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000119312526389400/0001193125-26-389400-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000119312526389400/d143428d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-389400
- JSON: https://secwatch.observer/filing/0001193125-26-389400.json
- Plain text: https://secwatch.observer/filing/0001193125-26-389400.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.